23 November 2022 - - New data on respiratory syncytial virus in the US, sourced on November 7, 2022, show that 90% of US emergency room and critical care physicians say they have treated patients with RSV over the prior two weeks--up from 81% during the two weeks preceding October 24, 2022--a 9 percentage-point increase, US-based life science and healthcare data and insights provider Apollo said.

Data continue to align with the CDC's RSV-Net surveillance1,2 of RSV-associated hospitalizations, which also showed a net increase during the same two week period.

The new data are from Wave 2 of a real-time tracking report on RSV released by InCrowd, a global pioneer of real-time, automated insights for the life science industry and an Apollo Intelligence (Apollo) brand.

Responding through InCrowd's mobile-integrated survey platform, validated physicians from the company's proprietary global panel were able to complete this research and share their frontline, real-world experiences in under 90 minutes.

Both severity and caseloads also increased in Wave 2 of the report as sourced by InCrowd's MicroTracker, real-time, automated tracking platform.

Sixty percent of doctors say the RSV cases they are treating are more severe than in previous years--a figure that also increased from 45% two weeks ago.

Doctors treated an average of 18 patients for RSV in the Wave 2 report, up from an average of 11 patients in Wave 1.

Forty-four percent of respondents in Wave 2 characterize the increase in RSV case numbers over the previous two weeks as very strong compared to 30% in Wave 1.

Wave 2 of the InCrowd RSV Tracker fielded Monday, November 7, 2022, in 90 minutes, and includes insights from n=100 ER and critical care doctors in the US, among them 62% who are based at community hospitals and 38% at academic hospitals.

Wave 1 of the InCrowd RSV Tracker fielded Monday, October 24th, 2022, in under five hours, with insights from n=103 ER and critical care doctors in the US, including 71% who are based at community hospitals and 29% at academic hospitals.

Data in both reports were obtained using a 1-minute MicroSurvey performed on InCrowd's agile, global market insights platform.

InCrowd's real-time tracking data on RSV is a complement to InCrowd Essentials syndicated research on the RSV market, a packaged solution that can help life science firms gauge awareness and opportunity in the evolving RSV therapeutic market.

In 2019, Apollo launched with the acquisition of InCrowd, a pioneer of real-time, automated insights for the life science industry.

To complement InCrowd and strengthen its global reach, in 2020, Apollo acquired Survey Healthcare Global, a global market leader of first-party healthcare data collection and custom survey solutions.

Apollo provides access to 2m healthcare stakeholders worldwide--including physicians, patients, caregivers, and allied healthcare professionals.

Apollo's 250+ employees support global pharmaceutical brands, market research agencies, and consultancies across 13 different countries in the Americas, Europe, and Asia. Apollo is a portfolio company of Frazier Healthcare Partners.